{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced%2FMetastatic+Non-Small+Cell+Lung+Cancer+%28NSCLC%29&page=34", "query": { "condition": "Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)", "page": 34 }, "page_size": 10 }, "pagination": { "page": 34, "page_size": 10, "total_count": 930, "total_pages": 93, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced%2FMetastatic+Non-Small+Cell+Lung+Cancer+%28NSCLC%29&page=35&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced%2FMetastatic+Non-Small+Cell+Lung+Cancer+%28NSCLC%29&page=33&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T12:23:57.821Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01248247", "title": "BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Erlotinib", "type": "DRUG" }, { "name": "AZD6244", "type": "DRUG" }, { "name": "MK-2206", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 334, "start_date": "2011-06-02", "completion_date": "2020-11-30", "has_results": true, "last_update_posted_date": "2022-01-12", "last_synced_at": "2026-10-16T12:23:57.821Z", "location_count": 2, "location_summary": "New Haven, Connecticut • Houston, Texas", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01248247" }, { "nct_id": "NCT00931008", "title": "Study to Evaluate SID 530 Compared to Taxotere", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "SID530, Taxotere", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SK Chemicals Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2009-10", "completion_date": "2011-01", "has_results": false, "last_update_posted_date": "2013-01-24", "last_synced_at": "2026-10-16T12:23:57.821Z", "location_count": 2, "location_summary": "Miami, Florida • Canton, Ohio", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00931008" }, { "nct_id": "NCT01727076", "title": "Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Recurrent Head and Neck Carcinoma", "Recurrent Non-Small Cell Lung Carcinoma", "Recurrent Renal Cell Carcinoma", "Recurrent Skin Carcinoma", "Stage III Renal Cell Cancer", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIA Non-Small Cell Lung Cancer AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIB Non-Small Cell Lung Cancer AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Stage IV Non-Small Cell Lung Cancer AJCC v7", "Stage IV Renal Cell Cancer" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Recombinant Human Interleukin-15", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 20, "start_date": "2013-02-15", "completion_date": "2016-06-30", "has_results": false, "last_update_posted_date": "2017-09-15", "last_synced_at": "2026-10-16T12:23:57.821Z", "location_count": 5, "location_summary": "Palo Alto, California • Bethesda, Maryland • Minneapolis, Minnesota + 2 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Seattle", "state": "Washington" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01727076" }, { "nct_id": "NCT03419559", "title": "Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "LN-145", "type": "BIOLOGICAL" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Iovance Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-02-28", "completion_date": "2024-12", "has_results": false, "last_update_posted_date": "2019-04-16", "last_synced_at": "2026-10-16T12:23:57.821Z", "location_count": 8, "location_summary": "La Jolla, California • Los Angeles, California • Louisville, Kentucky + 5 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Morristown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03419559" }, { "nct_id": "NCT00955942", "title": "Flaxseed Supplement in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Undergoing Chemotherapy and Radiation Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer", "Radiation Toxicity" ], "interventions": [ { "name": "flaxseed", "type": "DIETARY_SUPPLEMENT" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 48, "start_date": "2007-12", "completion_date": "2018-06", "has_results": false, "last_update_posted_date": "2020-04-02", "last_synced_at": "2026-10-16T12:23:57.821Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00955942" }, { "nct_id": "NCT07005102", "title": "A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Non-Squamous Non-Small Cell Lung Cancer", "c-MET" ], "interventions": [ { "name": "Standard of Care", "type": "DRUG" }, { "name": "Telisotuzumab Adizutecan", "type": "DRUG" }, { "name": "Osimertinib (Osi)", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 854, "start_date": "2025-08-03", "completion_date": "2036-11", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-16T12:23:57.821Z", "location_count": 18, "location_summary": "Chandler, Arizona • Duarte, California • Irvine, California + 15 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07005102" }, { "nct_id": "NCT03647488", "title": "Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Capmatinib", "type": "DRUG" }, { "name": "Spartalizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2018-12-26", "completion_date": "2020-09-07", "has_results": true, "last_update_posted_date": "2022-01-24", "last_synced_at": "2026-10-16T12:23:57.821Z", "location_count": 1, "location_summary": "Fayetteville, Arkansas", "locations": [ { "city": "Fayetteville", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03647488" }, { "nct_id": "NCT00075751", "title": "Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Non-small Cell Lung Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Non-small Cell Lung Cancer" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2004-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-28", "last_synced_at": "2026-10-16T12:23:57.821Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00075751" }, { "nct_id": "NCT02222922", "title": "A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "PF-06647020 Q3W", "type": "DRUG" }, { "name": "fluconazole", "type": "DRUG" }, { "name": "PF-06647020 Q2W", "type": "DRUG" }, { "name": "PF-06647020 combined with Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 138, "start_date": "2014-10-17", "completion_date": "2019-11-05", "has_results": true, "last_update_posted_date": "2020-12-17", "last_synced_at": "2026-10-16T12:23:57.821Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Sacramento, California + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02222922" }, { "nct_id": "NCT05785741", "title": "A Study of DB-1310 in Advanced/Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "DB-1310", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Osimertinib", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "DualityBio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1000, "start_date": "2023-08-17", "completion_date": "2028-04-30", "has_results": false, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-10-16T12:23:57.821Z", "location_count": 15, "location_summary": "Sacramento, California • Santa Monica, California • Coral Gables, Florida + 12 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Margate", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05785741" } ] }